Lightlake Therapeutics Inc (OTCBB:LLTP) is pleased to announce the appointment of Geoffrey Wolf as a Director of the company. Geoffrey Wolf is resident in both Switzerland and South Africa. After studying for his MBA in London UK he has had a 35 year career in international commerce and industry. This has encompassed Minerals, Pharmaceuticals, Metals, Mining, Oil and Gas, Hospitality and Real Estate.

As an Investor he has participated in transactions involving Amoun, a leading Egyptian Pharmaceutical Company, and Birgi Mefar, a major Turkish Pharmaceutical Contract Manufacturing and Services Company.

Dr Michael Sinclair, Chairman of Lightlake Therapeutics Inc commented: "Geoffrey Wolf brings to Lightlake a global experience of successful entrepreneurial business. We very much look forward to the significant contribution we are confident he will make to our company."

Geoffrey Wolf commented: "Obesity and the associated Binge Eating Disorder are major global healthcare challenges. Dr David Sinclair's pioneering research into the use of Opiate Antagonists holds great promise as a means of addressing these disorders. I relish the opportunity to internationalize access to Lightlake's products."

About Lightlake Therapeutics

Lightlake Therapeutics is an early stage biopharmaceutical company aiming to build a solid platform of pharmacological treatments based on our expertise using opioid antagonists. Other significant developments include the use of an opioid antagonist nasal spray to address binge-eating obesity. A Phase II trial of this product in Helsinki is due to be completed during 2011.

This press release contains forward-looking statements. These statements relate to future events or our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our or our industry's actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed, implied or inferred by these forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as "may," "will," "should," "could," "would," "expects," "plans," "intends," "anticipates," "believes,” estimates," "predicts," "projects," "potential" or "continue" or the negative of such terms and other comparable terminology. These statements are only predictions based on our current expectations and projections about future events. You should not place undue reliance on these statements. Actual events or results may differ materially. In evaluating these statements, you should specifically consider various factors. These and other factors may cause our actual results to differ materially from any forward-looking statement. We undertake no obligation to update any of the forward-looking statements after the date of this presentation to conform those statements to reflect the occurrence of unanticipated events, except as required by applicable law.

www.lightlaketherapeutics.com

Opiant Pharmaceuticals (NASDAQ:OPNT)
Historical Stock Chart
Von Jun 2024 bis Jul 2024 Click Here for more Opiant Pharmaceuticals Charts.
Opiant Pharmaceuticals (NASDAQ:OPNT)
Historical Stock Chart
Von Jul 2023 bis Jul 2024 Click Here for more Opiant Pharmaceuticals Charts.